Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AUPH Aurinia Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AUPH
Price (delayed)
$8.8
Market cap
$1.19B
P/E Ratio
30.34
Dividend/share
N/A
EPS
$0.29
Enterprise value
$1.2B
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
Highlights
Aurinia Pharmaceuticals's EPS has surged by 169% YoY
The net income has soared by 164% YoY
AUPH's equity is down by 7% since the previous quarter and by 2.6% year-on-year
Key stats
What are the main financial stats of AUPH
Market
Valuations
Earnings
Shares outstanding
135.1M
Market cap
$1.19B
Enterprise value
$1.2B
Price to earnings (P/E)
30.34
Price to book (P/B)
3.45
Price to sales (P/S)
4.94
EV/EBIT
25.86
EV/EBITDA
18.22
EV/Sales
4.85
Revenue
$247.3M
Gross profit
$218.23M
Operating income
$30.41M
Net income
$39.85M
EBIT
$46.43M
EBITDA
$65.88M
Free cash flow
$64M
Per share
Balance sheet
Liquidity
EPS
$0.29
EPS diluted
$0.28
Free cash flow per share
$0.46
Book value per share
$2.55
Revenue per share
$1.78
TBVPS
$3.6
Total assets
$504.85M
Total liabilities
$154.66M
Debt
$77.91M
Equity
$350.19M
Working capital
$337.36M
Debt to equity
0.22
Current ratio
5.93
Quick ratio
5.16
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
26.6%
Gross margin
88.2%
Net margin
16.1%
Operating margin
12.3%
Return on assets
7.5%
Return on equity
10.8%
Return on invested capital
9.8%
Return on capital employed
10.6%
Return on sales
18.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUPH stock price
How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
-1.46%
1 week
15.94%
1 month
8.78%
1 year
50.17%
YTD
-2%
QTD
3.9%
Financial performance
How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$247.3M
Gross profit
$218.23M
Operating income
$30.41M
Net income
$39.85M
Gross margin
88.2%
Net margin
16.1%
The net income has soared by 164% YoY
Aurinia Pharmaceuticals's net margin has surged by 149% YoY
The operating income has soared by 140% year-on-year
The operating margin has soared by 131% YoY
Price vs fundamentals
How does AUPH's price correlate with its fundamentals
Growth
What is Aurinia Pharmaceuticals's growth rate over time
Valuation
What is Aurinia Pharmaceuticals stock price valuation
P/E
30.34
P/B
3.45
P/S
4.94
EV/EBIT
25.86
EV/EBITDA
18.22
EV/Sales
4.85
Aurinia Pharmaceuticals's EPS has surged by 169% YoY
The price to book (P/B) is 19% higher than the last 4 quarters average of 2.9 but 9% lower than the 5-year quarterly average of 3.8
AUPH's equity is down by 7% since the previous quarter and by 2.6% year-on-year
The stock's P/S is 99% less than its 5-year quarterly average of 827.1 but 5% more than its last 4 quarters average of 4.7
The revenue has increased by 29% YoY and by 5% from the previous quarter
Efficiency
How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC has soared by 185% year-on-year
The ROE has soared by 166% YoY
The company's return on assets has surged by 165% YoY
Aurinia Pharmaceuticals's return on sales has surged by 162% YoY
Dividends
What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUPH.
Financial health
How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's current ratio has increased by 30% from the previous quarter and by 6% YoY
The quick ratio rose by 28% since the previous quarter and by 5% year-on-year
Aurinia Pharmaceuticals's debt is 78% lower than its equity
The company's debt to equity fell by 12% YoY but it rose by 4.8% QoQ
Aurinia Pharmaceuticals's debt has decreased by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.